id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-E-0261-0006,FDA,FDA-2006-E-0261,USPTO to Bristol-Myers Squibb Company - Notice of Final Determination,Other,LET-Letter,2007-11-19T05:00:00Z,2007,11,,,2008-05-28T16:43:42Z,,0,0,0900006480457a3a
FDA-2006-E-0261-0005,FDA,FDA-2006-E-0261,FDA/CDER to the USPTO - Letter,Other,LET-Letter,2007-09-18T04:00:00Z,2007,9,,,2008-05-28T16:41:52Z,,0,0,0900006480457a38
FDA-2006-E-0261-0004,FDA,FDA-2006-E-0261,Determination of Regulatory Review Period for Purposes of Patent Extension - BARACLUDE - Federal Register Notice -,Notice,N-Notice,2007-02-27T05:00:00Z,2007,2,2007-02-22T05:00:00Z,2007-04-25T03:59:59Z,2008-05-28T16:40:17Z,,0,0,0900006480457a36
FDA-2006-E-0261-0003,FDA,FDA-2006-E-0261,FDA/CDER to the USPTO - Letter,Other,LET-Letter,2007-02-07T05:00:00Z,2007,2,,,2008-05-28T16:37:47Z,,0,0,0900006480457a35
FDA-2006-E-0261-0002,FDA,FDA-2006-E-0261,USPTO to FDA/CDER - Letter,Other,LET-Letter,2007-01-09T05:00:00Z,2007,1,,,2008-05-28T16:36:04Z,,0,0,0900006480457a34